Design refinement from beginning of processing to end
The Progenokine Process takes in all aspects of regeneration with a unique design to utilize not just cells, but their signaling molecules (growth factors and cytokines.)
Our processing techniques go above and beyond the industry standard to ensure verifiable conformance, efficiency for practitioners and safety for patients. The Progenokine Process is the premier alternative to current industry cryopreservation media.
NOT JUST CELLS – Cells need signaling molecules
Cells need their signaling molecules to recruit recipient cells and modulate the micro-environment. The Progenokine Process was designed with this in mind: to utilize the cells and signaling molecules (growth factors and cytokines) to produce a product with the highest impact possible.
Burst Biologics and the Progenokine Process ensure a consistent, reliable product.
The Progenokine Process utilizes non-toxic, DMSO-free cryopreservation media while still maintaining a high level of cell integrity and viability.
Why say no to DMSO?
DMSO is a penetrative substance that may adversely interact with the cells at room temperature. With the potential to penetrate the membrane, DMSO can also adversely interact with internal cellular pathways – causing them to not function properly.
Most HCT/Ps that are frozen and contain DMSO require washing before they are applied to the patient. This additional process takes valuable time away from the physicians, their staff, and their patients.
The patent pending Progenokine processing technique incorporates unique breakthroughs in cryoprotection exclusive to Burst Biologics.